Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T. Ozaki Y, et al. Breast Cancer. 2018 May;25(3):343-349. doi: 10.1007/s12282-018-0836-x. Epub 2018 Jan 22. Breast Cancer. 2018. PMID: 29357022 Free PMC article.
[Malignant Spinal Cord Compression].
Aoyama Y, Kondoh C, Anno M, Takahashi T, Yoshino K, Kizawa R, Ozaki Y, Tanabe Y, Miura Y, Takano T. Aoyama Y, et al. Gan To Kagaku Ryoho. 2020 Jun;47(6):875-880. Gan To Kagaku Ryoho. 2020. PMID: 32541159 Japanese.
[Hypopituitarism].
Yamanaka T, Tatsushima K, Kondoh C, Takemura K, Masuda J, Ozaki Y, Tanabe Y, Miura Y, Takano T. Yamanaka T, et al. Gan To Kagaku Ryoho. 2020 Jun;47(6):885-890. Gan To Kagaku Ryoho. 2020. PMID: 32541161 Japanese.
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
Izawa N, Shitara K, Yonesaka K, Yamanaka T, Yoshino T, Sunakawa Y, Masuishi T, Denda T, Yamazaki K, Moriwaki T, Okuda H, Kondoh C, Nishina T, Makiyama A, Baba H, Yamaguchi H, Nakamura M, Hyodo I, Muro K, Nakajima TE. Izawa N, et al. Target Oncol. 2020 Oct;15(5):623-633. doi: 10.1007/s11523-020-00750-w. Target Oncol. 2020. PMID: 32960408 Clinical Trial.
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, Tomita Y, Oyama M, Masumori N, Kojima T, Matsumoto H, Chen M, Li M, Matsuda K, Tanaka Y, Rini BI, Uemura H. Tamada S, et al. Int J Clin Oncol. 2022 Jan;27(1):154-164. doi: 10.1007/s10147-021-02014-7. Epub 2021 Nov 20. Int J Clin Oncol. 2022. PMID: 34800178 Free PMC article. Clinical Trial.
42 results